TrialSignal
Clinical trial intelligence report
A Phase II Study of Rebeccamycin Analogue NSC 655649 in Patients With Metastatic Colorectal Cancer (IMT Codes 23988, 23989, 23993)
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT00005085-Jul 28, 2026
NCT ID
NCT00005085
Status
COMPLETED
Phase
PHASE2
Sponsor
National Cancer Institute (NCI)
Executive brief
Investment-Ready Snapshot
A Phase II Study of Rebeccamycin Analogue NSC 655649 in Patients With Metastatic Colorectal Cancer (IMT Codes 23988, 23989, 23993) is a PHASE2 clinical asset sponsored by National Cancer Institute (NCI) in Colorectal Cancer. SEO and diligence focus: becatecarin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00005085
Indication
Colorectal Cancer
Modality
small molecule
Target
becatecarin
Intervention
becatecarin
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.